Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio che confronta Zanubrutinib + Rituximab rispetto a Bendamustine + Rituximab nei partecipanti con linfoma mantellare non trattato (MANGROVE)

25 settembre 2026 aggiornato da: BeOne Medicines

Uno studio di fase 3 randomizzato, in aperto, multicentrico che confronta Zanubrutinib (BGB-3111) più Rituximab rispetto a Bendamustina più Rituximab in pazienti con linfoma mantellare non trattato in precedenza che non sono idonei al trapianto di cellule staminali

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Panoramica dello studio

Descrizione dettagliata

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

510

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, 2605
        • Canberra Hospital
    • New South Wales
      • Concord, New South Wales, Australia, 2139
        • Concord Repatriation General Hospital
      • Cudgen, New South Wales, Australia, 2487
        • The Tweed Valley Hospital
      • Darlinghurst, New South Wales, Australia, 2010
        • Saint Vincents Hospital Sydney
      • Gosford, New South Wales, Australia, 2250
        • Gosford Hospital
      • Waratah, New South Wales, Australia, 2298
        • Calvary Mater Newcastle
    • Queensland
      • Birtinya, Queensland, Australia, 4575
        • Sunshine Coast Hospital and Health Service
      • South Brisbane, Queensland, Australia, 4101
        • Icon Cancer Foundation
    • South Australia
      • Bedford PK, South Australia, Australia, 5042
        • Flinders Medical Centre
    • Tasmania
      • Hobart, Tasmania, Australia, 7000
        • Royal Hobart Hospital
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Monash Health
      • Fitzroy, Victoria, Australia, 3065
        • St Vincents Hospital Melbourne
      • Frankston, Victoria, Australia, 3199
        • Peninsula Private Hospital
      • Geelong, Victoria, Australia, 3220
        • Barwon Health the Geelong Hospital
    • Western Australia
      • Perth, Western Australia, Australia, 6000
        • Royal Perth Hospital
      • Linz, Austria, 4020
        • Ordensklinikum Linz Gmbh Elisabethinen
      • Salzburg, Austria, 5020
        • Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg
      • Vienna, Austria, 1090
        • Medical University Vienna Oncology
      • Bruges, Belgio, 8000
        • Az Sint Jan Brugge
      • Brussels, Belgio, 1090
        • Universitair Ziekenhuis Brussel
      • Edegem, Belgio, 2650
        • Uz Antwerpen
      • Kortrijk, Belgio, 8500
        • Az Groeninge Campus Loofstraat
      • Liège, Belgio, 4000
        • Centre Hospitalier Universitaire (Chu) de Liege Site Du Sart Tilman
      • Yvoir, Belgio, 5530
        • Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8M2
        • The Ottawa Hospital
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Ciusss de Lestrie Chus
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100044
        • Peking University Peoples Hospital
      • Beijing, Beijing Municipality, Cina, 100050
        • Beijing Friendship Hospital, Capital Medical University
    • Fujian
      • Fuzhou, Fujian, Cina, 350001
        • Fujian Medical University Union Hospital
      • Quanzhou, Fujian, Cina, 362000
        • Quanzhou First Affliated Hospital of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510080
        • Guangdong Provincial Peoples Hospital
      • Guangzhou, Guangdong, Cina, 510515
        • Nanfang Hospital of Southern Medical University
      • Guangzhou, Guangdong, Cina, 510060
        • Sun Yat Sen University Cancer Center
    • Heilongjiang
      • Harbin, Heilongjiang, Cina, 150000
        • Harbin Medical University Cancer Hospital
    • Henan
      • Zhengzhou, Henan, Cina, 450000
        • Henan Cancer Hospital
    • Hubei
      • Wuhan, Hubei, Cina, 430030
        • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    • Hunan
      • Changsha, Hunan, Cina, 410013
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210029
        • Jiangsu Province Hospital
      • Nanjing, Jiangsu, Cina, 210008
        • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
      • Xuzhou, Jiangsu, Cina, 221000
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, Cina, 330006
        • The First Affiliated Hospital of Nanchang University Branch Donghu
    • Jilin
      • Changchun, Jilin, Cina, 130021
        • The First Hospital of Jilin University
      • Changchun, Jilin, Cina, 130021
        • Jilin Cancer Hospital
    • Liaoning
      • Shenyang, Liaoning, Cina, 110004
        • Shengjing Hospital of China Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200000
        • Fudan University Shanghai Cancer Center
      • Shanghai, Shanghai Municipality, Cina, 200120
        • Shanghai East Hospital
    • Sichuan
      • Chengdu, Sichuan, Cina, 610041
        • West China Hospital, Sichuan University
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Cina, 300060
        • Tianjin Medical University Cancer Institute and Hospital
      • Tianjin, Tianjin Municipality, Cina, 300020
        • Institute of Hematology and Hospital of Blood Disease
    • Xinjiang
      • Ürümqi, Xinjiang, Cina, 830000
        • Affiliated Cancer Hospital of Xinjiang Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Zhejiang, Cina, 310003
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Ningbo, Zhejiang, Cina, 315000
        • Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)
      • Bordeaux, Francia, 33076
        • Centre de Lutte Contre Le Cancer Institut Bergonie
      • Brest, Francia, 29200
        • Chru de Brest Hospital Morvan
      • Dijon, Francia, J4V 2H1
        • Chu Dijon
      • Grenoble, Francia, 38043
        • Chu Grenoble Alpes
      • Le Mans, Francia, 72037
        • Centre Hospitalier Le Mans
      • Lille, Francia, 59000
        • Hopital Claude Huriez Chu Lille
      • Marseille, Francia, 13009
        • Institut Paoli Calmettes
      • Nantes, Francia, 44093
        • Centre Hospitalier Universitaire Nantes Hotel Dieu
      • Paris, Francia, 75005
        • Institut Curie
      • Paris, Francia, 75015
        • Necker University Hospital
      • PierreBenite, Francia, 69495
        • Chu Hopital Lyon Sud
      • Poitiers, Francia, 86000
        • Centre Hospitalier Universitaire de Poitier Hopital de La Miletrie Hopital Jean Bernard
      • Quimper, Francia, 29000
        • Ch Cornouaille
      • Toulouse, Francia, 31059
        • Iuc Toulouse Oncopole
      • Cologne, Germania, 50937
        • Uniklinik Koln (Aor)
      • Heidelberg, Germania, 69120
        • Universitatsklinikum Heidelberg
      • Munich, Germania, 81377
        • Dept of Medicine Iii, University Hospitallmu
      • Ulm, Germania, 89081
        • Universitaetsklinikum Ulm, Innere Medizin Iii
      • Wuppertal, Germania, 42283
        • Petrus Krankenhaus Wuppertal
      • Yokohama, Giappone, 221-0855
        • Yokohama Municipal Citizens Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Giappone, 460-0001
        • National Hospital Organization Nagoya Medical Center
      • Toyohashi, Aichi-ken, Giappone, 441-8570
        • Toyohashi Municipal Hospital
    • Chiba
      • Chiba, Chiba, Giappone, 260-8717
        • Chiba Cancer Center
    • Fukuoka
      • Kurume, Fukuoka, Giappone, 830-0011
        • Kurume University Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, Giappone, 730-8619
        • Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Giappone, 241-8515
        • Kanagawa Cancer Center
    • Kumamoto
      • Kumamoto, Kumamoto, Giappone, 860-0008
        • National Hospital Organization Kumamoto Medical Center
    • Kyoto
      • Kyoto, Kyoto, Giappone, 602-8566
        • University Hospital, Kyoto Prefectural Univ of Medicine
    • Miyagi
      • Sendai, Miyagi, Giappone, 980-8574
        • Tohoku University Hospital
    • Okayama-ken
      • Kurashikishi, Okayama-ken, Giappone, 710-8602
        • Kurashiki Central Hospital
      • Okayama, Okayama-ken, Giappone, 701-1192
        • National Hospital Organization Okayama Medical Center
    • Osaka
      • Osaka, Osaka, Giappone, 545-8586
        • Osaka Metropolitan University Hospital
      • Osakashi, Osaka, Giappone, 543-8555
        • Osaka Red Cross Hospital
    • Tokyo
      • Chuoku, Tokyo, Giappone, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Tokyo, Giappone, 113-8519
        • Tokyo Medical and Dental University Hospital
      • Cork, Irlanda, t12DC4A
        • Cork University Hospital
      • Dublin, Irlanda, D7
        • Mater Misericordiae University Hospital
      • Dublin, Irlanda, D8
        • St Jamess Hospital
      • Galway, Irlanda, H91 YR71
        • University Hospital Galway
      • Limerick, Irlanda, V94F858
        • University Hospital Limerick
      • Waterford, Irlanda, X91 ER8E
        • University Hospital Waterford
      • Alessandria, Italia, 15121
        • Azienda Ospedaliera Nazionale Ssantonio E Biagio E Cesare Arrigo
      • Bologna, Italia, 40138
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Genova, Italia, 16132
        • Azienda Ospedaliera Universitaria San Martino
      • Milan, Italia, 20162
        • Niguarda Cancer Center Division of Hematology
      • Novara, Italia, 28100
        • Aou Maggiore Della Carita
      • Palermo, Italia, 90146
        • Aoor Villa Sofia Cervello
      • Pisa, Italia, 56126
        • Aou Pisana, Stabilimento Di Santa Chiara
      • Ravenna, Italia, 48121
        • Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia
      • Reggio Emilia, Italia, 42123
        • Azienda Unita Sanitaria Locale Irccs
      • Roma, Italia, 00161
        • Universita Degli Studi La Sapienza
      • Siena, Italia, 53100
        • Aou Senese Policlinico Santa Maria Alle Scotte
      • Torino, Italia, 10126
        • Ao Citta Della Salute E Della Scienza Di Torino Presidio O
      • Verona, Italia, 37142
        • University of Verona
      • Christchurch, Nuova Zelanda, 8011
        • Christchurch Hospital (Canterbury Health Laboratories)
      • Tauranga, Nuova Zelanda, 3112
        • Tauranga Hospital
      • Goes, Olanda, 4462 RA
        • Admiraal de Ruijter Ziekenhuis
      • Groningen, Olanda, 9713 GZ
        • University of Medical Center Groningen (Umcg)
      • Nieuwegein, Olanda, 3435 CM
        • St Antonius Ziekenhuis, Randd Interne Geneeskunde (F)
      • Nijmegen, Olanda, 6525 GA
        • Albert Schweitzer Ziekenhuis
      • Rotterdam, Olanda, 3015 GD
        • Erasmus Mc
      • The Hague, Olanda, 2545 CH
        • Hagaziekenhuis
      • Bydgoszcz, Polonia, 85-168
        • Szpital Uniwersytecki Nr Im Dr Jana Biziela
      • Chorzów, Polonia, 41-503
        • Silesian Healthy Blood Clinic
      • Gdansk, Polonia, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Gdask, Polonia, 80-219
        • Copernicus Podmiot Leczniczy Sp Z Oo Wojewodzkie Centrum Onkologii
      • Gdynia, Polonia, 81-519
        • Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
      • Krakow, Polonia, 30-727
        • Pratia McM Krakow
      • Legnica, Polonia, 59-220
        • Wojewodzki Szpital Specjalistyczny W Legnicy
      • Lodz, Polonia, 93-510
        • Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
      • Lublin, Polonia, 20-090
        • Centrum Onkologii Ziemi Lubelskiej
      • Warsaw, Polonia, 02-776
        • Instytut Hematologii I Transfuzjologii W Warszawie
      • Wałbrzych, Polonia, 58-309
        • Specjalistyczny Szpital Im Dr Alfreda Sokolowskiego
      • Wroclaw, Polonia, 50-556
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
      • Lisbon, Portogallo, 1099-023
        • Instituto Portugues Oncologia de Lisboa Francisco Gentil, Epe
      • Lisbon, Portogallo, 1649-035
        • Chuln Hospital de Santa Maria
      • Porto, Portogallo, 4099-001
        • Centro Hospitalar Universitario Porto
      • Porto, Portogallo, 4200-072
        • Instituto Portugues de Oncologia Do Porto Francisco Gentil, Epe
      • Abergavenny, Regno Unito, NP7 7EG
        • Aneurin Bevan University Health Board
      • Birmingham, Regno Unito, B9 5SS
        • Birmingham Heartlands Hospital
      • Dudley, Regno Unito, DY1 2HQ
        • Russells Hall Hopsital
      • Sutton, Regno Unito, SM2 5PT
        • Royal Marsden Nhs Foundation Royal Marsden Hospital
      • Bucharest, Romania, 022328
        • Institutul Clinic Fundeni
      • Iași, Romania, 700483
        • Institutul Regional de Oncologie Iasi
      • Moscow, Russia, 142770
        • Gbuz Mmcc Kommunarka Dzm
    • Moscow
      • Moscow, Moscow, Russia, 125284
        • Clinical Hospital, Sp Botkin
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Russia, 191024
        • Fgu Russian Scientific Research Institute of Hematology and Transfusiology
      • Saint Petersburg, Sankt-Peterburg, Russia, 194291
        • Leningrad Regional Clinic and Hospital
      • Barcelona, Spagna, 08035
        • Hospital Universitario Vall Dhebron
      • Barcelona, Spagna, 08916
        • Ico Hug Trias I Pujol
      • Barcelona, Spagna, 08908
        • Institut Catala Doncologia
      • Girona, Spagna, 17007
        • Ico Girona
      • Madrid, Spagna, 28046
        • Hospital Universitario La Paz
      • Madrid, Spagna, 28040
        • Start Madrid Fundacion Jimenez Diaz
      • Madrid, Spagna, 28033
        • Md Anderson Cancer Center Madrid Spain
      • Madrid, Spagna, 28009
        • Hospital Universitario Gregorio Maranon
      • Málaga, Spagna, 29010
        • Hospital Regional Universitario de Malaga
      • Seville, Spagna, 41013
        • Hospital Universitario Virgen Del Rocio
    • California
      • Orange, California, Stati Uniti, 92868
        • Chao Family Comprehensive Cancer Center
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Rush University Medical Center
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215-5400
        • Beth Israel Deaconess Medical Center (Bidmc)
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • University of Michigan Health System
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89169
        • Comprehensive Cancer Centers of Nevada
    • New York
      • New York, New York, Stati Uniti, 10029
        • Icahn School of Medicine At Mount Sinai
      • Westbury, New York, Stati Uniti, 11590
        • Clinical Research Alliance, Inc
    • Oregon
      • Portland, Oregon, Stati Uniti, 97213
        • Providence Portland Medical Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15224
        • West Penn Hospital
    • Texas
      • Houston, Texas, Stati Uniti, 77030-4009
        • The University of Texas Md Anderson Cancer Center
      • Lubbock, Texas, Stati Uniti, 79410
        • Joe Arrington Cancer Research and Treatment Center
    • Washington
      • Seattle, Washington, Stati Uniti, 98109
        • Seattle Cancer Care Alliance
      • Tainan, Taiwan, 704
        • National Cheng Kung University Hospital
      • Tainan, Taiwan, 736
        • Chi Mei Hospital Liouying
      • Taipei, Taiwan, 114
        • Tri Service General Hospital
      • Ankara, Turchia (Türkiye), 06620
        • Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital
      • Ankara, Turchia (Türkiye), 6500
        • Gazi University
      • Ankara, Turchia (Türkiye), 06700
        • Hematoloji Ve Hematolik Onkoloji Tani Ve Tedavi Merezi
      • Edirne, Turchia (Türkiye), 22030
        • Tr Trakya University Health Research and Application Center (Hospital)
      • Istanbul, Turchia (Türkiye), 34365
        • Vkv American Hospital
      • Mersin, Turchia (Türkiye), 33000
        • Mersin Universitesi Tip Fakultesi Hastanesi
      • Cherkasy, Ucraina, 18009
        • Cherkasy Regional Oncology Dispensary
      • Dnipro, Ucraina, 49102
        • Municipal Non Profit Enterprise City Clinical Hospital
      • Kiev, Ucraina, 3022
        • National Cancer Institute
      • Lviv, Ucraina, 79044
        • Si Institute of Blood Pathology and Transfusion Medicine Nams of Ukraine, Hematology Department

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

60 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key Inclusion Criteria:

  1. ≥70 years of age at the time of informed consent, OR ≥60 and <70 years of age with comorbidities precluding autologous stem cell transplantation
  2. Histologically confirmed diagnosis of MCL
  3. No prior systemic treatments for MCL
  4. Measurable disease by CT/MRI
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  6. Adequate marrow and organ function

Key Exclusion Criteria:

  1. Known central nervous system involvement by lymphoma
  2. Participants for whom the goal of therapy is tumor debulking prior to stem cell transplant
  3. Clinically significant cardiovascular disease
  4. History of severe bleeding disorder
  5. Unable to swallow capsules or disease significantly affecting gastrointestinal function
  6. Active fungal, bacterial and/or viral infection requiring systemic therapy
  7. Requires ongoing treatment with a strong CYP3A inhibitor or inducer

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm A: zanubrutinib plus rituximab

Participants will receive zanubrutinib plus rituximab, followed by zanubrutinib monotherapy until Independent Review Committee (IRC)-confirmed disease progression.

Administered as two 80 mg capsules by mouth twice a day

Altri nomi:
  • Brukinsa
  • BGB-3111

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Comparatore attivo: Arm B: bendamustine plus rituximab

Participants will receive bendamustine plus rituximab, followed by observation.

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival (PFS) determined by independent central review
Lasso di tempo: Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PFS by investigator assessment
Lasso di tempo: Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years
Overall response rate (ORR)
Lasso di tempo: Up to approximately 7 years

ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), determined by independent central review and by investigator assessment.

Up to approximately 7 years
Duration of response (DOR)
Lasso di tempo: Up to approximately 7 years

DOR, as determined by independent central review and by investigator assessment, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first.

Up to approximately 7 years
Overall survival (OS)
Lasso di tempo: Up to approximately 7 years

OS is defined as the time from randomization to the date of death due to any reason.

Up to approximately 7 years
Time to Response (TTR)
Lasso di tempo: Up to approximately 7 years

TTR, as determined by independent central review and by investigator assessment, and defined as the time from randomization to the first documentation of response.

Up to approximately 7 years
Rate of complete response (CR) or complete metabolic response
Lasso di tempo: Up to approximately 7 years

Rate of CR or complete metabolic response is defined as the percentage of participants who achieve a CR or complete metabolic response, determined by independent central review and by investigator assessment.

Up to approximately 7 years
Participant-reported outcomes (PROs) as assessed by the European Quality of Life 5-Dimension 5 Level Questionnaire (EQ-5D-5L)
Lasso di tempo: Up to approximately 7 years

EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system involves five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Participants may choose from the following response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health.

Up to approximately 7 years
PROs as assessed by the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Lasso di tempo: Up to approximately 7 years

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).

Up to approximately 7 years
Number of participants with adverse events and serious adverse events
Lasso di tempo: Up to approximately 7 years

Number of participants with adverse events and serious adverse events, including laboratory values, vital signs, and physical examination findings.

Up to approximately 7 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Study Director, BeOne Medicines

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 agosto 2019

Completamento primario (Effettivo)

27 aprile 2026

Completamento dello studio (Stimato)

30 settembre 2031

Date di iscrizione allo studio

Primo inviato

27 giugno 2019

Primo inviato che soddisfa i criteri di controllo qualità

27 giugno 2019

Primo Inserito (Effettivo)

28 giugno 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Periodo di condivisione IPD

See plan description

Criteri di accesso alla condivisione IPD

See plan description

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi